S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$1.18
+1.7%
$2.09
$0.39
$18.00
$5.59M3.526,071 shs6,887 shs
Biostage, Inc. stock logo
BSTG
Biostage
$4.45
$4.45
$4.45
$4.45
$61.78M-1.021,847 shsN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$0.51
-3.8%
$0.50
$0.26
$1.15
$18.32M1.5841,342 shs32,280 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.83
-3.3%
$3.89
$1.03
$5.07
$118.70M2.44184,335 shs85,245 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
+2.33%-19.80%-40.20%-76.59%-66.09%
Biostage, Inc. stock logo
BSTG
Biostage
0.00%0.00%0.00%0.00%-27.64%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-0.28%-4.07%+5.16%-3.09%-54.91%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-3.28%-11.34%-10.30%+15.36%+75.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
0.8934 of 5 stars
2.03.00.00.02.61.70.6
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.8639 of 5 stars
3.33.00.00.02.11.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/A
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/A$3.80652.48% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00108.88% Upside

Current Analyst Ratings

Latest STIM, BSTG, SSKN, and ARTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K69.92N/AN/A($2.43) per share-0.49
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/A($0.26) per shareN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$33.36M0.53N/AN/A$0.37 per share1.36
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.61N/AN/A$1.18 per share3.25

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)
Biostage, Inc. stock logo
BSTG
Biostage
-$6.07M-$0.58N/AN/AN/AN/A-174.43%N/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-$10.83M-$0.31N/AN/AN/A-32.47%-52.50%-17.66%5/20/2024 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/14/2024 (Estimated)

Latest STIM, BSTG, SSKN, and ARTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    
2/20/2024Q1 2024
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A-$0.57-$0.57-$0.57N/A$0.05 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.16
0.04
Biostage, Inc. stock logo
BSTG
Biostage
N/A
2.73
2.73
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
1.19
1.28
1.06
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Biostage, Inc. stock logo
BSTG
Biostage
N/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
32.43%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Biostage, Inc. stock logo
BSTG
Biostage
15.30%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
40.43%
Neuronetics, Inc. stock logo
STIM
Neuronetics
7.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
84.74 million4.53 millionNot Optionable
Biostage, Inc. stock logo
BSTG
Biostage
713.88 million11.76 millionNot Optionable
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
11435.06 million20.89 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.79 millionOptionable

STIM, BSTG, SSKN, and ARTH Headlines

SourceHeadline
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%
marketbeat.com - April 12 at 3:58 PM
New Study Offers Hope for Depression Patients Undergoing TMS TherapyNew Study Offers Hope for Depression Patients Undergoing TMS Therapy
msn.com - April 12 at 1:57 AM
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
globenewswire.com - April 10 at 8:31 AM
Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)
marketbeat.com - April 6 at 7:36 PM
Neuronetics Stock (NASDAQ:STIM), Quotes and News SummaryNeuronetics Stock (NASDAQ:STIM), Quotes and News Summary
benzinga.com - April 5 at 5:38 AM
Neuronetics (STIM) FDA-Cleared NeuroStar to Aid in DepressionNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
zacks.com - April 1 at 11:56 AM
Neuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hires
msn.com - April 1 at 1:05 AM
Neurostar cleared for use in adolescent depressionNeurostar cleared for use in adolescent depression
bioworld.com - March 29 at 12:15 AM
FDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatmentFDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatment
medicaldialogues.in - March 29 at 12:15 AM
FDA Clears NeuroStars TMS Therapy for Adolescents with Major Depressive DisorderFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
msn.com - March 29 at 12:15 AM
Neuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateNeuronetics, Inc. (NASDAQ:STIM) Short Interest Update
marketbeat.com - March 28 at 11:57 AM
Neuronetics wins FDA clearance for device to treat adolescents with depressionNeuronetics wins FDA clearance for device to treat adolescents with depression
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 27 at 4:30 PM
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
markets.businessinsider.com - March 27 at 6:41 AM
Neuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depressionNeuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression
fiercebiotech.com - March 27 at 6:41 AM
Neuronetics (STIM) "Market Perform" Rating Reiterated at William BlairNeuronetics' (STIM) "Market Perform" Rating Reiterated at William Blair
marketbeat.com - March 26 at 3:29 PM
TMS Device NeuroStar Cleared as Add-On Treatment for Adolescent DepressionTMS Device NeuroStar Cleared as Add-On Treatment for Adolescent Depression
empr.com - March 26 at 3:49 AM
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depressionNeuronetics’s NeuroStar wins FDA clearance for adolescents with depression
msn.com - March 25 at 10:48 PM
Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
finanznachrichten.de - March 25 at 12:07 PM
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
marketwatch.com - March 25 at 12:07 PM
Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication
markets.businessinsider.com - March 25 at 12:07 PM
FDA clears Neuronetics’ neurostim for adolescents with depressionFDA clears Neuronetics’ neurostim for adolescents with depression
massdevice.com - March 25 at 12:07 PM
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
globenewswire.com - March 25 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Arch Therapeutics logo

Arch Therapeutics

OTCMKTS:ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Biostage logo

Biostage

OTCMKTS:BSTG
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
STRATA Skin Sciences logo

STRATA Skin Sciences

NASDAQ:SSKN
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also provides TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.